Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript

By Yahoo! Finance | Nov 14, 2024 at 09:15 PM EST

Inovio Pharmaceuticals discussed progress on DNA medicine platform development in Q3 2024, focusing on INO-3107 for RRP treatment. Positive immunology data, regulatory discussions, and financial discipline were highlighted. Plans for BLA submission, commercialization, and pipeline advancement were emphasized.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.